Atrial Fibrillation and Chronic Heart Failure: Common Pathogenetic Pathways, Approaches to Treatment, Potential for Application of Artificial Intelligence

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Atrial fibrillation (AFib) and chronic heart failure (CHF) are frequently encountered cardiovascular conditions that share common causes and tend to coexist in some patients. Such coexistence represents a major issue due to augmentation of symptoms severity, rapid deterioration, and poor prognosis. Management of patients with AFib and CHF is challenging due to limitations in pharmacotherapy and decreased efficacy of cardiac interventions. In this review we focus on crucial pathogenic components of AFib and CHF coexistence, key treatment approaches and discuss potential for implementation of artificial intelligence.

Full Text

Restricted Access

About the authors

Madina D. Utsumueva

E.I. Chazov National Medical Research Center in Cardiology

Author for correspondence.
Email: utsumueva@gmail.com
ORCID iD: 0000-0003-0746-8012
SPIN-code: 2443-5240

MD, PhD

Russian Federation, Moscow

Nikolay Yu. Mironov

E.I. Chazov National Medical Research Center in Cardiology; Plekhanov Russian University of Economics

Email: nikmir.7ko@gmail.com
ORCID iD: 0000-0002-6086-6784
SPIN-code: 3542-5572

MD, PhD

Russian Federation, Moscow; Moscow

Sergey P. Golitsyn

E.I. Chazov National Medical Research Center in Cardiology

Email: golitsyn@umail.ru
ORCID iD: 0000-0001-9913-9974

MD, PhD, Professor

Russian Federation, Moscow

Yulia A. Dolgusheva

E.I. Chazov National Medical Research Center in Cardiology; Plekhanov Russian University of Economics

Email: dol.85@mail.ru
ORCID iD: 0000-0002-9326-2071
SPIN-code: 9349-4400

MD, PhD

Russian Federation, Moscow; Moscow

Valery V. Beregovykh

Russian Academy of Sciences

Email: beregovykh@ramn.ru
ORCID iD: 0000-0002-0210-4570
SPIN-code: 5940-7554

PhD, in Technical Sciences, Professor, Academician of the RAS

Russian Federation, Moscow

Nikolay L. Schimanowsky

Plekhanov Russian University of Economics

Email: shimannn@yandex.ru
ORCID iD: 0000-0001-8887-4420
SPIN-code: 5232-8230

MD PhD, Professor, Corresponding Member of the RAS

Russian Federation, Moscow

References

  1. Wijesurendra RS, Casadei B. Mechanisms of atrial fibrillation. Heart. 2019;105(24):1860–1867. doi: https://doi.org/10.1136/heartjnl-2018-3
  2. Ziaeian B, Fonarow GC. Epidemiology and aetiology of heart failure. Nat Rev Cardiol. 2016;13(6):368–337. doi: https://doi.org/10.1038/nrcardio.2016.25
  3. Лукьянов М.М., Марцевич С.Ю., Мареев Ю.В., и др. Больные с сочетанием фибрилляции предсердий и хронической сердечной недостаточности в клинической практике: сопутствующие заболевания, медикаментозное лечение и исходы // Рациональная фармакотерапия в кардиологии. — 2021. — Т. 17. — № 6. — C. 816–824. [Loukianov MM, Martsevich SYu, Mareev YuV, et al. Patients with a Combination of Atrial Fibrillation and Chronic Heart Failure in Clinical Practice: Comorbidities, Drug Treatment and Outcomes. Rational Pharmacotherapy in Cardiology. 2021;17(6):816-824. (In Russ.)] doi: https://doi.org/10.20996/1819-6446-2021-12-05
  4. Santhanakrishnan R, Wang N, Larson MG, et al. Atrial fibrillation begets heart failure and vice versa: temporal associations and differences in preserved versus reduced ejection fraction. Circulation. 2016;133(5):484–492. doi: https://doi.org/10.1161/CIRCULATIONAHA.115.018614
  5. Мареев Ю.В., Поляков Д.С., Виноградова Н.Г., и др. ЭПОХА: Эпидемиология фибрилляции предсердий в репрезентативной выборке европейской части Российской Федерации // Кардиология. — 2022. — Т. 62. — № 4. — С. 12–19. [Mareev YuV, Polyakov DS, Vinogradova NG, et al. Epidemiology of atrial fibrillation in a representative sample of the European part of the Russian Federation. Analysis of EPOCH-CHF study. Kardiologiia. 2022;62(4):12–19. (In Russ.)] doi: https://doi.org/10.18087/cardio.2022.4.n199
  6. Komajda M, Anker SD, Cowie MR, et al. QUALIFY Investigators (2016) Physicians’ adherence to guideline-recommended medications in heart failure with reduced ejection fraction: data from the QUALIFY global survey. Eur J Heart Fail. 2016;18(5):514–522. doi: https://doi.org/10.1002/ejhf.510
  7. Gopinathannair R, Chen LY, Chung MK, et al. Managing Atrial Fibrillation in Patients with Heart Failure and Reduced Ejection Fraction: A Scientific Statement From the American Heart Association. Circ Arrhythm Electrophysiol. 2021;14(6):HAE0000000000000078. doi: https://doi.org/10.1161/HAE.0000000000000078
  8. Жиров И.В., Сафронова Н.В., Осмоловская Ю.Ф. Прогностическое значение фибрилляции предсердий у пациентов с сердечной недостаточностью с разной фракцией выброса левого желудочка: результаты многоцентрового регистра РИФ-ХСН // Российский кардиологический журнал. — 2021. — Т. 26. — № 1. — C. 44–57. [Zhirov IV, Safronova NV, Osmolovskaya Yu F. Prognostic value of atrial fibrillation in patients with heart failure and different left ventricular ejection fraction: results of the multicenter RIF-CHF register. Russian Journal of Cardiology. 2021;26(1):44–57. (In Russ.)] doi: https://doi.org/10.15829/1560-4071-2021-4200
  9. Гаглоева Д.А., Миронов Н.Ю., Лайович Л.Ю., и др. Взаимосвязь фибрилляции предсердий и хронической сердечной недостаточности. Современные подходы к лечению // Кардиологический вестник. — 2021. — Т. 16. — № 2. — С. 5–14. [Gagloeva DA, Mironov NYu, Laiovich LYu, et al. Atrial fibrillation and chronic heart failure: interrelationship and approaches to treatment. Russian Cardiology Bulletin. 2021;16(2):5–14. (In Russ.)] doi: https://doi.org/10.17116/Cardiobulletin2021160215
  10. Redfield MM, Kay GN, Jenkins LS, et al. Tachycardia-related cardiomyopathy: a common cause of ventricular dysfunction in patients with atrial fibrillation referred for atrioventricular ablation. Mayo Clin Proc. 2000;75(8):790–795. doi: https://doi.org/10.4065/75.8.790
  11. Guichard JB, Nattel S. Atrial cardiomyopathy: a useful notion in cardiac disease management or a passing fad? J Am Coll Cardiol. 2017;70(6):756–765. doi: https://doi.org/10.1016/j.jacc.2017.06.033
  12. Schotten U, Dobrev D, Platonov PG, et al. Current controversies in determining the main mechanisms of atrial fibrillation. J Intern Med. 2016;279(5):428–438. doi: https://doi.org/10.1111/joim.12492
  13. Brecht A, Oertelt-Prigione S, Seeland U, et al. Left atrial function in preclinical diastolic dysfunction: two-dimensional speckle-tracking echocardiography-derived results from the BEFRI trial. J Am Soc Echocardiogr. 2016;29(8):750–758. doi: https://doi.org/10.1016/j.echo.2016.03.013
  14. Sobue Y, Watanabe E, Lip GYH, et al. Thromboembolisms in atrial fibrillation and heart failure patients with a preserved ejection fraction (HFpEF) compared to those with a reduced ejection fraction (HFrEF). Heart Vessels. 2018;33(4):403–412. doi: https://doi.org/10.1007/s00380-017-1073-5
  15. Hill K, Sucha E, Rhodes E, et al. Amiodarone, Verapamil, or Diltiazem Use with Direct Oral Anticoagulants and the Risk of Hemorrhage in Older Adults. CJC Open. 2022;4(3):315–323. doi: https://doi.org/10.1016/j.cjco.2021.11.002
  16. Roy D, Talajic M, Nattel S, et al. Atrial fibrillation and congestive heart failure investigators Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008;358(25):2667–2677. doi: https://doi.org/10.1056/NEJMoa0708789
  17. Rillig A, Magnussen C, Ozga AK, et al. Early Rhythm Control Therapy in Patients with Atrial Fibrillation and Heart Failure. Circulation. 2021;144(11):845–858. doi: https://doi.org/10.1161/CIRCULATIONAHA.121.056323
  18. Lehmann MH, Hardy S, Archibald D, et al. Sex difference in risk of torsade de pointes with d,l-sotalol. Circulation. 1996;94(10):2535–2541. doi: https://doi.org/10.1161/01.cir.94.10.2535
  19. Weinfeld MS, Drazner MH, Stevenson WG, et al. Early outcome of initiating amiodarone for atrial fibrillation in advanced heart failure. J Heart Lung Transplant. 2000;19(7):638–643. doi: https://doi.org/10.1016/s1053-2498(00)00123-6
  20. Prabhu S, Taylor AJ, Costello BT, et al. (2017) Catheter ablation versus medical rate control in atrial fibrillation and systolic dysfunction: the CAMERA-MRI study. J Am Coll Cardiol. 2017;70(16):1949–1961. doi: https://doi.org/10.1016/j.jacc.2017.08.041
  21. Marrouche NF, Brachmann J, Andresen D, et al. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med. 2018;378(5):417–427. doi: https://doi.org/10.1056/NEJMoa1707855
  22. Turagam MK, Garg J, Whang W, et al. Catheter Ablation of Atrial Fibrillation in Patients with Heart Failure: A Meta-analysis of Randomized Controlled Trials. Ann Intern Med. 2019;170(1):41–50. doi: https://doi.org/10.7326/M18-0992
  23. Richter S, Di Biase L, Hindricks G. Atrial fibrillation ablation in heart failure. Eur Heart J. 2019;40(8):663–671. doi: https://doi.org/10.1093/eurheartj/ehy778
  24. Rathore SS, Curtis JP, Wang Y, et al. Association of Serum Digoxin Concentration and Outcomes in Patients with Heart Failure. JAMA. 2003;289(7):871–878. doi: https://doi.org/10.1001/jama.289.7.871
  25. Deedwania PC, Singh BN, Ellenbogen K, et al. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators. Circulation. 1998;98(23):2574–2579. doi: https://doi.org/10.1161/01.cir.98.23.2574
  26. Gasparini M, Regoli F, Galimberti P, et al. Cardiac resynchronization therapy in heart failure patients with atrial fibrillation. Europace. 2009;11(Suppl 5):v82–86. doi: https://doi.org/10.1093/europace/eup273
  27. Martin CA, Lambiase PD. Pathophysiology, diagnosis and treatment of tachycardiomyopathy. Heart. 2017;103(19):1543–1552. doi: https://doi.org/10.1136/heartjnl-2016-310391
  28. Атабегашвили М.Р., Щекочихин Д.Ю., Громыко Г.А., и др. Кардиомиопатия, индуцированная тахикардией. Клиническое наблюдение // Терапевтический архив. — 2021. — Т. 93. — № 4. — C. 465–469. [Atabegashvili MR, Shchekochikhin DYu, Gromyko GA, et al. Tachicardia-induced cardiomyopathy. Case report. Terapevticheskii Arkhiv (Ter. Arkh.). 2021;93(4):465–469. (In Russ.)] doi: https://doi.org/10.26442/00403660.2021.04.200803
  29. Medi C, Kalman JM, Haqqani H, et al. Tachycardia-mediated cardiomyopathy secondary to focal atrial tachycardia: long-term outcome after catheter ablation. J Am Coll Cardiol. 2009;53(19):1791–1797. doi: https://doi.org/10.1016/j.jacc.2009.02.014
  30. Ling LH, Kalman JM, Ellims AH, et al. Diffuse ventricular fibrosis is a late outcome of tachycardia-mediated cardiomyopathy after successful ablation. Circ Arrhythm Electrophysiol. 2013;6(4):697–704. doi: https://doi.org/10.1161/CIRCEP.113.000681
  31. Isaksen JL, Baumert M, Hermans ANL, et al. Artificial intelligence for the detection, prediction, and management of atrial fibrillation. Herzschr Elektrophys. 2022;33(1):34–41. doi: https://doi.org/10.1007/s00399-022-00839-x
  32. Caturano, Alfredo MD; Spiezia, Serenella MD; Brunelli, Vincenzo MD; Galiero, Raffaele MD; Sasso, Ferdinando Carlo MD, PhD. Polypharmacy and Major Adverse Events in Atrial Fibrillation. J Cardiovasc Pharmacol. 2022;80(6):781–782. doi: https://doi.org/10.1097/FJC.0000000000001363
  33. Sánchez de la Nava AM, Atienza F, Bermejo J, et al. Artificial intelligence for a personalized diagnosis and treatment of atrial fibrillation. Am J Physiol Heart Circ Physiol. 2021;320(4):H1337–H1347. doi: https://doi.org/10.1152/ajpheart.00764.2020
  34. Christopoulos G, Graff-Radford J, Lopez CL, et al. Artificial intelligence-electrocardiography to predict incident atrial fibrillation: a population-based study. Circ Arrhythm Electrophysiol. 2020;13(12):e009355. doi: https://doi.org/10.1161/CIRCEP.120.009355
  35. Рытова А.И., Хлебус Э.Ю., Шевцов А.Е., и др. Современные вероятностно-статистические подходы к поиску вариантов нуклеотидной последовательности, ассоциированных с комплексными заболеваниями // Генетика. — 2017. — Т. 53. — № 10. — С. 1153–1169. [Rytova AI, Khlebus EYu, Shevtsov AE, et al. Modern Probabilistic and Statistical Approaches to Search for Nucleotide Sequence Options Associated with Integrated Diseases. Genetics. 2017;53(10):1153–1169. (In Russ.)] doi: https://doi.org/10.7868/S0016675817100083
  36. Ярославская Е.И., Дьячков С.М., Горбатенко Е.А. Применение аппарата искусственных нейронных сетей в прогнозировании фибрилляции предсердий у мужчин с ишемической болезнью сердца // Сибирский журнал клинической и экспериментальной медицины. — 2020. — Т. 35. — № 4. — С. 119–127. [Yaroslavskaya EI, Dyachkov SM, Gorbatenko EA. Artifi cial neural networks in prediction of atrial fi brillation in men with coronary artery disease. The Siberian Journal of Clinical and Experimental Medicine. 2020;35(4):119–127. (In Russ.)] doi: https://doi.org/10.29001/2073-8552-2020-35-4-119-127
  37. Perez MV, Mahaffey KW, Hedlin H, et al. Large-scale assessment of a smartwatch to identify atrial fibrillation. N Engl J Med. 2019;381(20):1909–1917. doi: https://doi.org/10.1056/ NEJMoa1901183
  38. Harmon DM, Sehrawat O, Maanja M, et al. Artificial Intelligence for the Detection and Treatment of Atrial Fibrillation. Arrhythm Electrophysiol Rev. 2023;12:e12. doi: https://doi.org/10.15420/aer.2022.31

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Common etiological factors and pathogenetic mechanisms in atrial fibrillation and heart failure (adapted translation from: Carlisle M.A. et al. J Am Coll Cardiol HF. 2019;7(6):447–456)

Download (330KB)
Indexing metadata
3. Fig. 2. Basic principles of antiarrhythmic and interventional treatment of atrial fibrillation in chronic heart failure

Download (256KB)
Indexing metadata
4. Fig. 3. Principles of drug and non-drug treatment for heart rate control in patients with atrial fibrillation and chronic heart failure

Download (255KB)
Indexing metadata

Copyright (c) 2024 "Paediatrician" Publishers LLC



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies